Delivery Order SPE2DB22D2211-SPE2DB25FSEAB
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,594.49 to AmerisourceBergen Drug Corp for the supply of Clindamycin Phosphate 1% Lotion in 60ml quantities. This competitively awarded, firm fixed-price delivery order was issued on August 19, 2025, with an ultimate completion date of August 20, 2025. The contract carries no set-aside designation, reflecting open competition among qualified pharmaceutical vendors. AmerisourceBergen's Corporate Office in Conshohocken, Pennsylvania...
- The Defense Logistics Agency awarded a $5,047.91 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Clindamycin Phosphate 1% Lotion (60 mL) under a firm fixed-price contract. This delivery order, which is not subject to any set-aside designation, is scheduled for completion by July 30, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Clindamycin Phosphate 1% Lotion in 60ml quantities under a firm fixed price contract. The award, valued at $4,684.17, was competitively awarded without set-aside designation and is scheduled for completion by August 26, 2025. AmerisourceBergen will perform this delivery order from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract valued at $1,348.34 to Amerisourcebergen Drug Corp's Corporate Office Division, a subsidiary of Amerisourcebergen Corporation. The contract is for the delivery of 4,564,327,564 units of Clindamycin Phosphate 1% Lotion in 60 mL containers. This order is under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. The IDC...
- The Defense Logistics Agency awarded a delivery order valued at $1,561.45 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Clindamycin 900 mg/50 mL in 5% dextrose solution (50 mL units). This firm fixed price, competitively awarded delivery order is set to be completed by July 31, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Clindamycin PH 900 mg/6 ml vials with a ceiling value of $17,867.22. This firm fixed-price delivery order, which is not set-aside, will be performed at the vendor's Corporate Office in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. The contract represents a routine pharmaceutical procurement under the defense medical...
- The Defense Logistics Agency awarded a $1,989.17 delivery order to AmerisourceBergen Drug Corp for the supply of Clindamycin 900 mg/50 ml in dextrose 5% water solution. This competitively awarded, firm fixed price contract was executed on July 18, 2025, with an ultimate completion date of July 21, 2025, and represents a child delivery order under a larger indefinite delivery contract. The product will be delivered to AmerisourceBergen's corporate headquarters location in Conshohocken,...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Clindamycin Phosphate 1% Lotion 60ML. The firm-fixed-price contract has a ceiling value of $1,591.79 and runs through January 31, 2023. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle...
- The Defense Logistics Agency awarded a delivery order valued at $1,235.36 to AmerisourceBergen Drug Corp for the supply of Clindamycin 900 mg/50 ml in D5W solution on August 4, 2025, with completion scheduled for August 5, 2025. This non-competitive delivery order represents a firm fixed price transaction executed under AmerisourceBergen's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999 and extending...
- The Defense Logistics Agency awarded a delivery order valued at $1,448.80 to AmerisourceBergen Drug Corp for the supply of Clindamycin PH 1% Solution in 60ml quantities. This contract, awarded on August 15, 2025, with an ultimate completion date of August 18, 2025, represents a firm fixed price delivery order with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a non-set-aside award, this delivery order was...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSEABDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Clindamycin Phosphate 1% Lotion in 60ml quantities, with a ceiling value of $3,766.03. This competitive award, issued with firm fixed pricing and no set-aside designation, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal military and veteran healthcare systems, providing comprehensive pharmaceutical products and medical supplies across multiple therapeutic domains. This delivery order is part of AmerisourceBergen's broader role as a prime pharmaceutical vendor supporting the Defense Health Agency and other federal healthcare systems. The company's federal contract portfolio demonstrates substantial capability in fulfilling military medical procurement requirements, with consistent awards involving generic and brand-name medications, vaccines, medical devices, and specialized healthcare commodities. The September 3, 2025 ultimate completion date reflects the typical expedited timeline for pharmaceutical delivery orders through the DLA supply chain, ensuring timely availability of medications for military medical facilities and personnel worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.8k | 9/2/25 |